Oruka Therapeutics Files 8-K on Shareholder Votes
Ticker: ORKA · Form: 8-K · Filed: Nov 18, 2024 · CIK: 907654
| Field | Detail |
|---|---|
| Company | Oruka Therapeutics, Inc. (ORKA) |
| Form Type | 8-K |
| Filed Date | Nov 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing-update
TL;DR
Oruka Therapeutics filed an 8-K on shareholder votes; check for governance updates.
AI Summary
Oruka Therapeutics, Inc. filed an 8-K on November 18, 2024, reporting on matters submitted to a vote of security holders as of November 14, 2024. The filing details the company's corporate information, including its address in Menlo Park, California, and its IRS number. It also lists former company names, indicating a history of mergers or name changes.
Why It Matters
This filing provides an update on corporate governance matters and potential changes affecting Oruka Therapeutics, Inc. and its shareholders.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure regarding shareholder votes and does not appear to contain significant new financial or operational risks.
Key Players & Entities
- Oruka Therapeutics, Inc. (company) — Registrant
- November 14, 2024 (date) — Earliest event reported
- November 18, 2024 (date) — Date of report
- Menlo Park, California (location) — Company address
- ARCA biopharma, Inc. (company) — Former company name
- NUVELO INC (company) — Former company name
- HYSEQ INC (company) — Former company name
FAQ
What specific matters were submitted to a vote of Oruka Therapeutics, Inc. security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on November 14, 2024.
What is Oruka Therapeutics, Inc.'s primary business classification?
Oruka Therapeutics, Inc. is classified under 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' with SIC code 2835.
Has Oruka Therapeutics, Inc. operated under different names previously?
Yes, Oruka Therapeutics, Inc. has operated under former names including ARCA biopharma, Inc., NUVELO INC, and HYSEQ INC.
Where is Oruka Therapeutics, Inc. located?
Oruka Therapeutics, Inc. is located at 855 Oak Grove Avenue, Suite 100, Menlo Park, California, 94025.
Filing Stats: 596 words · 2 min read · ~2 pages · Grade level 13 · Accepted 2024-11-18 16:10:14
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value ORKA The Nasdaq Global Ma
Filing Documents
- ea0221692-8k_oruka.htm (8-K) — 26KB
- 0001213900-24-099645.txt ( ) — 195KB
- orka-20241114.xsd (EX-101.SCH) — 3KB
- orka-20241114_lab.xml (EX-101.LAB) — 33KB
- orka-20241114_pre.xml (EX-101.PRE) — 22KB
- ea0221692-8k_oruka_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On November 14, 2024, Oruka Therapeutics, Inc. (the " Company ") held its Special Meeting of Stockholders (the " Special Meeting "). Set forth below is a brief description of each matter considered and voted upon at the Special Meeting, together with the final tally of the number of votes cast for or against, as well as the number of abstentions and broker non-votes as to each such matter. A more complete description of each matter is set forth in the Company's definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission on October 18, 2024. Proposal 1: Approval of Conversion of Series A Preferred Stock to Common Stock The Company's stockholders approved the issuance of shares of the Company's common stock upon conversion of the Company's Series A Non-Voting Convertible Preferred Stock, par value $0.001 per share, issued in September 2024. The tabulation of votes on this matter was as follows: Shares voted for: 30,598,476 Shares voted against: 6,026 Shares abstaining 1,089 There were no broker non-votes for this proposal. Proposal 2: Approval of an Adjournment of the Special Meeting, if Necessary or Appropriate, to Solicit Additional Proxies The Company's stockholders approved an adjournment of the Special Meeting, if necessary or appropriate, to solicit additional proxies. The tabulation of votes on this matter was as follows: Shares voted for: 29,294,720 Shares voted against: 1,309,805 Shares abstaining 1,066 There were no broker non-votes for this proposal.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Oruka Therapeutics, Inc. By: /s/ Paul Quinlan Name: Paul Quinlan Title: General Counsel Dated: November 18, 2024